<DOC>
	<DOCNO>NCT02835976</DOCNO>
	<brief_summary>This Phase I study design determine excretion balance radiocarbon , sum carbon-14 ( 14C ) -labeled TRO19622 14C-metabolites , investigate pharmacokinetics metabolic profile TRO19622 ( olesoxime ) healthy participant .</brief_summary>
	<brief_title>A Study Excretion Balance Radiocarbon Pharmacokinetics Metabolic Profile TRO19622 ( Olesoxime )</brief_title>
	<detailed_description />
	<criteria>Body mass index ( BMI ) 20.0 28.0 kilogram per metersquared ( kg/m^2 ) body weight least 60 kilogram ( kg ) Fitzpatrick skin type le ( &lt; ) 4 Good health accord medical history , physical examination , laboratory parameter , vital sign , 12lead electrocardiogram ( ECG ) Negative urine test drug abuse Negative alcohol breath test Negative test hepatitis human immunodeficiency virus ( HIV ) Use effective contraception 3 month beyond study participant , among sexually active nonvasectomized participant females partner childbearing potential Concomitant recent medication use within 2 week prior Day 1 , except paracetamol Use enzymeinducing drug within 2 month prior Day 1 Any medical condition may alter pharmacokinetics olesoxime affect interpretation study result Irregular bowel movement Drug addiction alcoholism Use nicotine product Participation another clinical study within 12 week prior Day 1 Exposure ionize radiation within one year prior Day 1</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>